Predicting risk of febrile neutropenia after CHOP chemotherapy.

被引：0
|
作者：
Chawla, RK [1 ]
Tompkins, KA [1 ]
Borgaonkar, MR [1 ]
Duggan, PR [1 ]
机构：
[1] Mem Univ Newfoundland, St John, NF A1C 5S7, Canada
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4585
引用
收藏
页码：230B / 230B
页数：1
相关论文
共 50 条
  • [21] Adjuvant taxane chemotherapy is associated with a significant risk of febrile neutropenia
    Caley, A.
    Bertelli, G.
    Rolles, M.
    Wagstaff, J.
    Moe, M.
    Pudney, D.
    EJC SUPPLEMENTS, 2010, 8 (03): : 70 - 70
  • [22] Risk factors for febrile neutropenia in cancer patients treated with chemotherapy
    Family, Leila
    Li, Yanli
    Chen, Lie H.
    Page, John
    Klippel, Zandra Karina
    Chao, Chun
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [23] The risk factors for febrile neutropenia during chemotherapy in children with malignancy
    Sulviani, Rini
    Idjradinata, Ponpon
    Raspati, Harry
    PAEDIATRICA INDONESIANA, 2007, 47 (02) : 83 - 87
  • [24] Risk of Febrile Neutropenia (FN) in Select Myelosuppressive Chemotherapy Regimens
    Family, Leila
    Yang, Su-Jau
    Khppel, Zandra
    Li, Yanli
    Page, John H.
    Rodriguez, Roberto
    Chao, Chun
    BLOOD, 2015, 126 (23)
  • [25] Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens
    Derek Weycker
    Xiaoyan Li
    John Edelsberg
    Rich Barron
    Alex Kartashov
    Hairong Xu
    Gary H. Lyman
    Supportive Care in Cancer, 2014, 22 : 3275 - 3285
  • [26] Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens
    Weycker, Derek
    Li, Xiaoyan
    Edelsberg, John
    Barron, Rich
    Kartashov, Alex
    Xu, Hairong
    Lyman, Gary H.
    SUPPORTIVE CARE IN CANCER, 2014, 22 (12) : 3275 - 3285
  • [27] A single dose of pegfilgrastim reduces the incidence of febrile neutropenia in various risk strata compared with daily filgrastim following myelosuppressive chemotherapy.
    Shogan, JE
    Koelbl, H
    Holmes, FA
    Liang, B
    Hackett, J
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S134 - S134
  • [28] Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy
    Lyman, GH
    Morrison, VA
    Dale, DC
    Crawford, J
    Delgado, DJ
    Fridman, M
    LEUKEMIA & LYMPHOMA, 2003, 44 (12) : 2069 - 2076
  • [29] Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma
    Lyman, GH
    Delgado, DJ
    CANCER, 2003, 98 (11) : 2402 - 2409
  • [30] GARENOXACIN PROPHYLAXIS FOR FEBRILE NEUTROPENIA AFTER CHEMOTHERAPY IN HEMATOLOGICAL MALIGNANCIES
    Nakamura, N.
    Tsurumi, H.
    Shibata, Y.
    Mabuchi, R.
    Kitagawa, J.
    Suetsugu, A.
    Kanemura, N.
    Goto, N.
    Hara, T.
    Moriwaki, H.
    ANNALS OF ONCOLOGY, 2013, 24 : 47 - 47
12345